Physician profile
Keith Angelo Johnstone
NPI 1760466049
$4,788.87
in general payments reported to CMS, 2019-2025
28 companies · $229 in 2025
The $229 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,017 · 2020: $418 · 2021: $478 · 2022: $1,022 · 2023: $795 · 2024: $831 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,821 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,821.43 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $735.38 | 2019-2025 | Farxiga, Wainua |
| Boston Scientific Corporation | $690.26 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Latitude Communicator Power Supply |
| Merck Sharp & Dohme LLC | $650.11 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.77 | 2019-2024 | Jardiance |
| Azurity Pharmaceuticals, INC. | $261.10 | 2023-2025 | Edarbi, Edarbi, Edarbyclor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $255.51 | 2019-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $251.17 | 2019-2024 | |
| Alnylam Pharmaceuticals INC. | $195.88 | 2021-2025 | Onpattro |
| Abiomed | $191.70 | 2023-2024 | Impella |
| Arbor Pharmaceuticals, INC. | $190.98 | 2019-2021 | |
| Novo Nordisk INC | $165.13 | 2019-2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $130.23 | 2019-2022 | |
| Abbott Laboratories | $121.93 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $120.93 | 2019-2024 | Opsumit |
| E.R. Squibb & Sons, L.L.C. | $92.14 | 2020-2025 | Camzyos, Eliquis |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $69.42 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $59.75 | 2021-2024 | |
| Kestra Medical Technology Services, INC. | $53.51 | 2023 | Assure Wcd |
| Ekos Corporation | $44.77 | 2019 | |
| Medtronic, INC. | $36.80 | 2021-2022 | |
| Bardy Diagnostics, INC. | $31.21 | 2020-2021 | |
| Scpharmaceuticals INC. | $24.23 | 2025 | |
| Impulse Dynamics (USA) INC. | $22.30 | 2024 | Optimizer |
| Astellas Pharma US INC | $20.52 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $20.14 | 2023 | Arcalyst |
| Angiodynamics, INC. | $15.13 | 2019 | |
| Pfizer INC. | $14.77 | 2023 | |
| Chiesi USA, INC. | $11.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Johnstone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.